[{"command":"settings","settings":{"pluralDelimiter":"\u0003","suppressDeprecationErrors":true,"ajaxPageState":{"libraries":"eJxLzi9K1U8pKi1IzNFLyUzMyU_XS8xKrNApSCxKTC9KLMgohskiRPRK8wpKk3IyizNSUwAiWxkF","theme":"upd","theme_token":null},"ajaxTrustedUrl":[],"user":{"uid":0,"permissionsHash":"22dcdfba032631beed6427d0f24bf0844dfb9bda62deaafe5cec74da1a30ffe0"}},"merge":true},{"command":"add_css","data":[{"rel":"stylesheet","media":"all","href":"\/sites\/default\/files\/css\/css_vc5cLuh4rhAN6znJCXfU-8zQmHR1yNnv8GD6Q85yEqA.css?delta=0\u0026language=en\u0026theme=upd\u0026include=eJxLzi9K1U8pKi1IzNFLzEqs0ElGEkjJTMzJT9cpSCxKTC9KLMgohkkgRPRK8wpKk3IyizNSUwBitB2R"}]},{"command":"add_js","selector":"body","data":[{"src":"\/sites\/default\/files\/js\/js_XNDFJOhCzYAJD-zg18t5sJXWQM2miB78WMDzbwhPN0g.js?scope=footer\u0026delta=0\u0026language=en\u0026theme=upd\u0026include=eJxLzi9K1U8pKi1IzNFLyUzMyU_XS8xKrAAAajEI0Q"}]},{"command":"openDialog","selector":"#drupal-modal","settings":null,"data":"\n          \u003Ca href=\u0022#\u0022\u003E\u003C\/a\u003E\n      \n  \u003Cp\u003E\u003Cspan\u003E\u003Cspan\u003E\u003Cspan\u003E\u003Cspan\u003E\u2018Commercial clinical trials in the UK: the Lord O\u2019Shaughnessy review\u2019 is an independent report commissioned by the UK Government and conducted by Lord O\u2019Shaughnessy, former Health Minister. The Review provides recommendations on how to transform commercial clinical trials in the UK.\u003C\/span\u003E\u003C\/span\u003E\u003C\/span\u003E\u003C\/span\u003E\u003C\/p\u003E\n\u003Cp\u003E\u003Cspan\u003E\u003Cspan\u003E\u003Cspan\u003E\u003Cspan\u003EThe report identifies a number of problems with clinical trials in the UK, including a failure to make full use of the NHS\u2019s data assets. To address this, the report makes a number of recommendations, summed up below:\u003C\/span\u003E\u003C\/span\u003E\u003C\/span\u003E\u003C\/span\u003E\u003C\/p\u003E\n\u003Cul\u003E\n\u003Cli\u003E\u003Cspan\u003E\u003Cspan\u003E\u003Cspan\u003E\u003Cspan\u003EEstablish processes for inviting patients to take part in research to enable research teams to contact patients to invite them to partake in clinical trials based on data held on them in patient records, databases and registries. \u003C\/span\u003E\u003C\/span\u003E\u003C\/span\u003E\u003C\/span\u003E\n\u003Cul\u003E\n\u003Cli\u003E\u003Cspan\u003E\u003Cspan\u003E\u003Cspan\u003E\u003Cspan\u003EThis is currently often blocked as researchers do not have consent to proactively contact patients\u003C\/span\u003E\u003C\/span\u003E\u003C\/span\u003E\u003C\/span\u003E\u003C\/li\u003E\n\u003Cli\u003E\u003Cspan\u003E\u003Cspan\u003E\u003Cspan\u003E\u003Cspan\u003EThe report proposes achieving this by establishing a common approach among health research agencies and updating guidance\u003C\/span\u003E\u003C\/span\u003E\u003C\/span\u003E\u003C\/span\u003E\u003C\/li\u003E\n\u003C\/ul\u003E\n\u003C\/li\u003E\n\u003Cli\u003E\u003Cspan\u003E\u003Cspan\u003E\u003Cspan\u003E\u003Cspan\u003EOffer everyone receiving genomic sequencing a standard consent for participating in research\u003C\/span\u003E\u003C\/span\u003E\u003C\/span\u003E\u003C\/span\u003E\n\u003Cul\u003E\n\u003Cli\u003E\u003Cspan\u003E\u003Cspan\u003E\u003Cspan\u003E\u003Cspan\u003EAt present, this is only offered to those receiving whole genome sequencing, meaning the majority of cancer and rare disease patients in the UK are not entered into databases that may be used for clinical trial recruitment or clinical research\u003C\/span\u003E\u003C\/span\u003E\u003C\/span\u003E\u003C\/span\u003E\u003C\/li\u003E\n\u003C\/ul\u003E\n\u003C\/li\u003E\n\u003Cli\u003E\u003Cspan\u003E\u003Cspan\u003E\u003Cspan\u003E\u003Cspan\u003EHold a national participatory process on patient consent to examine how to achieve greater data usage for research in a trustworthy way, with an aim of establishing a position on proactively contacting patients to take part in clinical trials\u003C\/span\u003E\u003C\/span\u003E\u003C\/span\u003E\u003C\/span\u003E\n\u003Cul\u003E\n\u003Cli\u003E\u003Cspan\u003E\u003Cspan\u003E\u003Cspan\u003E\u003Cspan\u003EThis would include addressing requirements to respect explicit consent to share data as part of research, overcoming issues where data belonging to patients who have consented to participating in research and sharing their data is not always released\u003C\/span\u003E\u003C\/span\u003E\u003C\/span\u003E\u003C\/span\u003E\u003C\/li\u003E\n\u003Cli\u003E\u003Cspan\u003E\u003Cspan\u003E\u003Cspan\u003E\u003Cspan\u003EIt would also involve seeking a publicly supported position around proactively contacting patients to take part in research, whilst also establishing mechanisms to enable people to opt out\u003C\/span\u003E\u003C\/span\u003E\u003C\/span\u003E\u003C\/span\u003E\u003C\/li\u003E\n\u003C\/ul\u003E\n\u003C\/li\u003E\n\u003Cli\u003E\u003Cspan\u003E\u003Cspan\u003E\u003Cspan\u003E\u003Cspan\u003ERoll out NHS England\u2019s Secure Data Environment Network and publish guidance for NHS organisations on engaging in research with industry\u003C\/span\u003E\u003C\/span\u003E\u003C\/span\u003E\u003C\/span\u003E\n\u003Cul\u003E\n\u003Cli\u003E\u003Cspan\u003E\u003Cspan\u003E\u003Cspan\u003E\u003Cspan\u003EThe report further recommends improving linkage between real-time clinical data and datasets held in SDEs\u003C\/span\u003E\u003C\/span\u003E\u003C\/span\u003E\u003C\/span\u003E\u003C\/li\u003E\n\u003C\/ul\u003E\n\u003C\/li\u003E\n\u003C\/ul\u003E\n\u003Cp\u003E\u003Cspan\u003E\u003Cspan\u003E\u003Cspan\u003E\u003Cspan\u003EThe Government has welcomed the recommendations from the review in principle, and announced a funding package of \u00a3121 million to improve commercial clinical trials alongside the publication of the review report, including \u00a381 million via NIHR to improve the transparency and accessibility of clinical trial data.\u003C\/span\u003E\u003C\/span\u003E\u003C\/span\u003E\u003C\/span\u003E\u003C\/p\u003E\n\n\n      \u003Ch3 class=\u0022modal--field-link--title\u0022\u003EFurther reading\u003C\/h3\u003E\n\u003Cul class=\u0022modal--field-link--list\u0022\u003E\n  \u003Cli\u003E\u003Ca href=\u0022https:\/\/www.gov.uk\/government\/publications\/commercial-clinical-trials-in-the-uk-the-lord-oshaughnessy-review\/commercial-clinical-trials-in-the-uk-the-lord-oshaughnessy-review-final-report\u0022\u003EO\u2019Shaughnessy Review\u003C\/a\u003E\u003C\/li\u003E\n  \u003Cli\u003E\u003Ca href=\u0022https:\/\/healthmedia.blog.gov.uk\/2023\/05\/25\/what-were-doing-to-speed-up-clinical-trials-in-the-uk\/\u0022\u003EDepartment of Health and Social Care blog about Government funding package anno\u2026\u003C\/a\u003E\u003C\/li\u003E\n\u003C\/ul\u003E\n\n    ","dialogOptions":{"width":"70%","height":"auto","dialogClass":"highlight-modal-dialog","closeOnEscape":"true","closeText":"Close text","buttons":{"button1":{"text":"Close","id":"close-button","onclick":"jQuery(\u0027.ui-icon-closethick\u0027).click()"}},"modal":true,"title":"O\u2019Shaughnessy Review (UK-wide) - 2023","classes":{"ui-dialog":"highlight-modal-dialog"}}}]